Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Neuroendocrine Tumors 20Meningioma 6Gastro-enteropancreatic neuroendocrine tumor 6Pheochromocytoma 3Paraganglioma 3Prostatic Neoplasms 2Neuroblastoma 2Medulloblastoma 2Glioma 2Glioblastoma 2Ependymoma 2Carcinoma, Merkel Cell 2Adenoma, Islet Cell 2Somatostatin Receptor-positive Neuroendocrine Tumor 1Sarcoma, Synovial 1Recurrence 1Pancreatic Neoplasms 1Osteosarcoma 1Neoplasms, Germ Cell and Embryonal 1Metastatic Digestive System Neuroendocrine Tumor G1 1Hypertension 1Extensive Stage Small Cell Lung Cancer 1Esthesioneuroblastoma, Olfactory 1Disease Progression 1Digestive System Neuroendocrine Tumor G1 1Diffuse Intrinsic Pontine Glioma 1Central Nervous System Neoplasms 1Carcinoma, Neuroendocrine 1Carcinoma 1Carcinoid Tumor 1

Interventions

Etoposide 3Carboplatin 3atezolizumab 2Cisplatin 2tislelizumab 1obinutuzumab 1lutetium Lu 177 dotatate 1durvalumab 1ceralasertib 1Paclitaxel 1Injections 1EC regimen 1Drug Therapy 1AMG 757 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Extensive Stage Small Cell Lung Cancer × lutetium Lu 177 dotatate × 1 year × Clear all
NCT05142696 2026-05-29

A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab

Novartis

Phase 1/2 Active not recruiting
24 enrolled
Thoracic

Extensive Stage Small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡